Does the Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Differ According to the Type of EGFR Mutation in Non-Small Cell Lung Cancer?

Korean Journal of Internal Medicine - South Korea
doi 10.3904/kjim.2016.190
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Korean Association of Internal Medicine

Related search

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Comparison of the Characteristics of Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations and EGFR‑tyrosine Kinase Inhibitor Treatment in Patients With Non‑small Cell Lung Cancer From Different Ethnic Groups

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2020English

Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

OncoTargets and Therapy
OncologyPharmacology
2019English

Comparison of the Efficacy of Icotinib in Patients With Non-Small-Cell Lung Cancer According to the Type of Epidermal Growth Factor Receptor Mutation

Molecular and Clinical Oncology
Cancer ResearchOncology
2016English

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Cancer Research
Cancer ResearchOncology
2017English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

JAMA - Journal of the American Medical Association
Medicine
2014English

Epidermal Growth Factor Tyrosine Kinase Inhibitor Therapy Inferior to Second-Line Chemotherapy in EGFR Wild-Type Non-Small Cell Lung Cancer Patients: Results of French Nationwide Observational Study

Translational Lung Cancer Research
Oncology
2017English

Correction: Real-World Management of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small-Cell Lung Cancer in the USA

PLoS ONE
Multidisciplinary
2019English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy